The Clinical Application Value Of New Castle Disease Virus Modified Autologous Tumor Vaccine (ATV-NDV) In Breast Cancer

Objective: Our study aimed to investigate the mechanisms of anti-tumor mechanisms and the clinical application value of new castle disease virus modified autologous tumor vaccine (ATV-NDV) in breast cancer's immunotherapy.Methods: Fresh tumor tissues were utilized to prepare ATV-NDV which then was used for 19 breast cancer patients's therapy. Cell immune functions of patients in different therapy phases were observed and side effect of the tumor vaccine was analyzed. The control group was the 20 breast cancer patients without inoculating with the tumor vaccine.Result: The cell immune functions of two groups were both suppressed before operation. After operation the immune functions of patients improved. The percentages of the cells of CD3+ T cell, CD4+ T cell, CD8+ T cell and NK cell were gradually increased in control group. And however, these values increased more obviously in therapy group after clinical with the tumor vaccine. There were significance differences in those values between patients before and after the ATV-NDV treatment. Moreover, these values after ATV-NDV treatment were remarkably higher than those in patients without ATV-NDV treatment.